TOKYO -- Japanese biotech company Takara Bio plans to mass produce novel coronavirus vaccinations as early as this year, President and CEO Koichi Nakao told Nikkei in an interview.
Pharmaceuticals
Takara Bio to mass-produce COVID-19 vaccine candidate
Japanese biotech company hopes to supply 200,000 people this year
Takara Bio says it has a DNA vaccine that can help a person's immune system successfully attack the new coronavirus. © Takara Bio
Read Next
Latest on Pharmaceuticals
